Opportunity Information: Apply for PA 10 290
Apply for PA 10 290
- The National Institutes of Health in the education health sector is offering a public funding opportunity titled "Research on Malignancies in the Context of HIV/AIDS (R01)" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 93.121 Oral Diseases and Disorders Research 93.393 Cancer Cause and Prevention Research 93.394 Cancer Detection and Diagnosis Research 93.395 Cancer Treatment Research 93.396 Cancer Biology Research.
- This funding opportunity was created on Sep 29, 2010 and posted on Sep 29, 2010.
- Applicants must submit their applications by Sep 7, 2013. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- Eligible applicants include: Public housing authorities/Indian housing authorities City or township governments Independent school districts Native American tribal organizations (other than Federally recognized tribal governments) Special district governments Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education Private institutions of higher education For profit organizations other than small businesses Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public and State controlled institutions of higher education Others (see text field entitled Additional Information on Eligibility for clarification) Native American tribal governments (Federally recognized) State governments Small businesses.
- Other Eligible Applicants include the following Alaska Native and Native Hawaiian Serving Institutions Eligible Agencies of the Federal Government Faith based or Community based Organizations Hispanic serving Institutions Historically Black Colleges and Universities (HBCUs) Indian/Native American Tribal Governments (Other than Federally Recognized) Non domestic (non U.S.) Entities (Foreign Organizations) Regional Organizations Tribally Controlled Colleges and Universities (TCCUs) U.S. Territory or Possession.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
Opportunity Summary:
The NIH funding opportunity titled "Research on Malignancies in the Context of HIV/AIDS (R01)" (Funding Opportunity Number PA 10 290) is a discretionary grant program that supports Research Project Grant (R01) applications focused on cancers that occur in people living with HIV or AIDS. Led by the National Cancer Institute (NCI) together with the National Institute of Dental and Craniofacial Research (NIDCR), the announcement is aimed at moving the field forward on how, why, and under what conditions malignancies arise and behave differently when an underlying HIV infection is present. At a high level, the program is looking for well-designed research projects that improve understanding of cancer risk, cancer development, disease progression, diagnosis, clinical course, and treatment outcomes in HIV-infected populations.
A central theme of the FOA is explaining the biological and clinical links between HIV-related immune dysfunction and cancer. The agencies emphasize research on etiologic factors and cofactors, meaning studies that clarify not only direct contributions of HIV infection but also the added roles of other influences such as co-infecting pathogens, host immune responses, inflammation, environmental exposures, behavioral factors, and treatment-related variables. The FOA highlights immunopathogenesis in particular, signaling interest in projects that examine how HIV-associated immune changes shape tumor initiation and progression, influence viral oncogenesis, affect tumor microenvironments, or alter responses to cancer therapy. The scope includes both AIDS-defining malignancies and non-AIDS-defining malignancies, reflecting the real-world shift in cancer patterns in the HIV population as antiretroviral therapy has extended life expectancy and changed the spectrum of disease.
The announcement also makes clear that proposals should produce actionable knowledge about clinical outcomes. One explicit objective is to generate information on the outcomes of cancers occurring in people with HIV, which can include survival, recurrence, treatment toxicity, treatment completion, cancer staging at diagnosis, patterns of metastasis, and differences in outcomes compared with HIV-uninfected populations. A second explicit objective is to identify the specific contributions of HIV infection itself, including how HIV may interact with other pathogens to drive cancer development and pathogenesis. This makes the FOA suitable for research that interrogates HIV interactions with oncogenic viruses and other infections, as well as studies that separate the effects of HIV, immunosuppression, antiretroviral therapy, and comorbidity profiles. The emphasis on diverse populations indicates that the NIH is encouraging research that accounts for demographic, geographic, and population-level differences that may shape risk and outcomes, including disparities in access to screening, prevention, and treatment.
From an administrative standpoint, this is an R01 mechanism, meaning it is intended for substantial, hypothesis-driven or otherwise clearly justified research projects with a defined set of aims, rigorous methods, and measurable deliverables. The announcement is categorized under health and education-related research activities and maps to multiple CFDA numbers spanning oral diseases and disorders research and several cancer research areas, including cause and prevention, detection and diagnosis, treatment, and cancer biology. That spread signals that the NIH is open to proposals across the cancer research continuum, from basic and mechanistic work through translational and clinical investigations, so long as the cancer questions are grounded in the context of HIV/AIDS.
Eligibility is broad. The FOA lists many U.S. domestic applicant types, including public and private institutions of higher education, nonprofits with or without 501(c)(3) status (other than higher education institutions), for-profit organizations (other than small businesses), small businesses, and multiple levels of government (state, county, city or township, special district). It also includes tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and independent school districts. Additional eligible applicants named in the eligibility information include historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, faith-based or community-based organizations, U.S. territories or possessions, regional organizations, eligible agencies of the federal government, and non-U.S. entities (foreign organizations). No cost sharing or matching is required, which reduces barriers to application for institutions that may have limited ability to provide additional funds.
Timing details show this opportunity was posted and created on September 29, 2010, with an original and current closing date of September 7, 2013, and an archive date of October 8, 2013, meaning it was time-limited and is now archived rather than open. The sponsoring agency is the National Institutes of Health, and the full announcement was hosted on the NIH grants guide site at the provided link. For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
Overall, this FOA targets research that clarifies why certain cancers are more common, behave differently, or lead to different outcomes in people with HIV/AIDS, and it encourages projects that connect mechanistic understanding with real clinical impact. Strong applications under this announcement would typically be expected to define a clear cancer-related problem in HIV populations, specify how HIV infection and related immune or infectious cofactors will be studied, and show how the results can improve diagnosis, risk stratification, prevention approaches, or treatment decision-making for malignancies in the context of HIV.
Frequently Asked Questions (FAQs)
What is the name of this NIH funding opportunity?
The funding opportunity is titled "Research on Malignancies in the Context of HIV/AIDS (R01)."
What is the Funding Opportunity Number (FON)?
The Funding Opportunity Number is PA 10 290.
What type of grant mechanism does this opportunity use?
This announcement uses the NIH Research Project Grant (R01) mechanism, intended for substantial, well-designed research projects with defined aims, rigorous methods, and measurable deliverables.
Which NIH Institutes or Centers are leading this announcement?
The announcement is led by the National Cancer Institute (NCI), together with the National Institute of Dental and Craniofacial Research (NIDCR).
What is the overall purpose of this funding opportunity?
The program supports R01 research focused on cancers that occur in people living with HIV or AIDS, with the goal of moving the field forward on how, why, and under what conditions malignancies arise and behave differently when underlying HIV infection is present.
What kinds of cancer-related questions does the FOA emphasize?
The FOA emphasizes research that improves understanding of cancer risk, cancer development, disease progression, diagnosis, clinical course, and treatment outcomes in HIV-infected populations.
Does the opportunity focus on the biological links between HIV and cancer?
Yes. A central theme is explaining biological and clinical links between HIV-related immune dysfunction and cancer, including how HIV-associated immune changes may shape tumor initiation and progression, viral oncogenesis, tumor microenvironments, and responses to cancer therapy.
What does the FOA mean by "etiologic factors and cofactors"?
It refers to research that clarifies not only direct contributions of HIV infection to cancer, but also additional influences such as co-infecting pathogens, host immune responses, inflammation, environmental exposures, behavioral factors, and treatment-related variables.
Is immunopathogenesis a specific area of interest in this FOA?
Yes. The FOA highlights immunopathogenesis, signaling interest in studies of how HIV-associated immune dysfunction influences cancer initiation, progression, and clinical behavior.
Are both AIDS-defining and non-AIDS-defining malignancies in scope?
Yes. The scope includes both AIDS-defining malignancies and non-AIDS-defining malignancies, reflecting changes in cancer patterns among people with HIV as antiretroviral therapy has extended life expectancy.
What clinical outcomes does the FOA explicitly mention as important?
The FOA explicitly mentions generating information on outcomes of cancers in people with HIV, including survival, recurrence, treatment toxicity, treatment completion, cancer staging at diagnosis, patterns of metastasis, and differences in outcomes compared with HIV-uninfected populations.
Does the FOA encourage comparisons between HIV-infected and HIV-uninfected populations?
Yes. The FOA notes interest in differences in outcomes compared with HIV-uninfected populations as part of understanding how malignancies behave in the context of HIV/AIDS.
What is the second explicit objective described in the announcement?
A second explicit objective is to identify the specific contributions of HIV infection itself, including how HIV may interact with other pathogens to drive cancer development and pathogenesis.
Does this opportunity support research on interactions between HIV and other infections?
Yes. The FOA is suitable for research that examines how HIV interacts with other pathogens, including oncogenic viruses and other infections, in ways that affect cancer development and progression.
Can proposed projects look at the effects of antiretroviral therapy (ART) in relation to cancer outcomes?
Yes. The description indicates interest in studies that separate the effects of HIV, immunosuppression, antiretroviral therapy, and comorbidity profiles when examining cancer risk and outcomes.
Is there an emphasis on diverse populations or disparities?
Yes. The FOA emphasizes diverse populations and encourages research that accounts for demographic, geographic, and population-level differences, including disparities in access to screening, prevention, and treatment.
Is the NIH open to proposals across the cancer research continuum?
Yes. The FOA maps to multiple cancer-related and oral health-related research areas (cause and prevention, detection and diagnosis, treatment, and cancer biology), signaling openness to basic, mechanistic, translational, and clinical investigations as long as the work is grounded in the context of HIV/AIDS.
What kinds of organizations are eligible to apply?
Eligibility is broad and includes U.S. public and private institutions of higher education; nonprofits with or without 501(c)(3) status (other than higher education institutions); for-profit organizations (other than small businesses); small businesses; and multiple levels of government (state, county, city or township, special district). It also includes tribal governments and tribal organizations, public housing authorities/Indian housing authorities, and independent school districts.
Are minority-serving institutions and community-based organizations eligible?
Yes. The eligibility information specifically includes historically Black colleges and universities (HBCUs), Hispanic-serving institutions, tribally controlled colleges and universities (TCCUs), Alaska Native and Native Hawaiian-serving institutions, and faith-based or community-based organizations.
Are U.S. territories or regional organizations eligible applicants?
Yes. The FOA includes U.S. territories or possessions and regional organizations among eligible applicants.
Are federal agencies eligible to apply?
Yes. The eligibility information includes eligible agencies of the federal government.
Are non-U.S. (foreign) organizations eligible to apply?
Yes. The FOA lists non-U.S. entities (foreign organizations) as eligible applicants.
Is cost sharing or matching required?
No. The FOA states that no cost sharing or matching is required.
When was this funding opportunity posted and created?
The opportunity was posted and created on September 29, 2010.
What were the closing and archive dates for this opportunity?
The original and current closing date was September 7, 2013, and the archive date was October 8, 2013.
Is this FOA currently open for applications?
No. Based on the closing date and archive date provided, this opportunity was time-limited and is now archived rather than open.
Who is the sponsoring agency?
The sponsoring agency is the National Institutes of Health (NIH).
Where was the full announcement hosted?
The full announcement was hosted on the NIH grants guide site (via the link referenced in the opportunity description).
Who is listed as the contact for access or technical issues?
For access or technical issues, the contact listed is the NIH Office of Extramural Research (OER) Webmaster at FBOWebmaster@OD.NIH.GOV.
What types of projects would typically be considered strong under this FOA?
Strong projects would typically define a clear cancer-related problem in HIV populations, specify how HIV infection and related immune or infectious cofactors will be studied, and show how results can improve diagnosis, risk stratification, prevention approaches, or treatment decision-making for malignancies in the context of HIV.
What is the main real-world motivation mentioned for including non-AIDS-defining cancers?
The description notes that antiretroviral therapy has extended life expectancy and changed the spectrum of disease, contributing to a shift in cancer patterns in the HIV population.
Browse more opportunities from the same agency: National Institutes of Health
Browse more opportunities from the same category: Education Health
Next opportunity: Research on Malignancies in the Context of HIV/AIDS (R21)
Previous opportunity: Combating Exploitative Child Labor by Promoting Sustainable Livelihoods and Educational Opportunities for Children in Egypt
USGrants.org Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for PA 10 290
[Watch] how do funding administrators access proposals?
Applicants also applied for:
Applicants who have applied for this opportunity (PA 10 290) also looked into and applied for these:
| Funding Opportunity |
|---|
| Research on Malignancies in the Context of HIV/AIDS (R21) Apply for PA 10 291 Funding Number: PA 10 291 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Tumor Microenvironment Network (TMEN) (U54) Apply for RFA CA 10 021 Funding Number: RFA CA 10 021 Agency: National Institutes of Health Category: Education Health Funding Amount: $700,000 |
| Animal and Biological Material Resource Centers (P40) Apply for PAR 11 001 Funding Number: PAR 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Cancer Center Support Grants (CCSGs) for NCI designated Cancer Centers (P30) Apply for PAR 11 005 Funding Number: PAR 11 005 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Comprehensive Partnerships to Reduce Cancer Health Disparities (U54) Apply for RFA CA 11 001 Funding Number: RFA CA 11 001 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Translational Scholar Career Awards in Pharmacogenomics and Personalized Medicine (K23) Apply for PA 11 009 Funding Number: PA 11 009 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R03) Apply for PA 11 008 Funding Number: PA 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R01) Apply for PA 11 006 Funding Number: PA 11 006 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Substance Use and Abuse, Risky Decision Making and HIV/AIDS (R21) Apply for PA 11 007 Funding Number: PA 11 007 Agency: National Institutes of Health Category: Education Health Funding Amount: $200,000 |
| HIV Infection of the Central Nervous System (R01) Apply for PA 11 014 Funding Number: PA 11 014 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| National Gene Vector Biorepository and Coordinating Center (P40) Apply for RFA RR 10 010 Funding Number: RFA RR 10 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Medical Marijuana Policy Research Exploring Trends and Impacts (R01) Apply for RFA DA 11 008 Funding Number: RFA DA 11 008 Agency: National Institutes of Health Category: Education Health Funding Amount: $500,000 |
| Molecular Genetics of Drug Addiction and Related Co Morbidities (R01) Apply for PA 11 026 Funding Number: PA 11 026 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Support Opportunity for Addiction Research (SOAR) for New Investigators (R03) Apply for RFA DA 11 010 Funding Number: RFA DA 11 010 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| The Development Of Frontal Cortex And Limbic System And Their Roles In Drug Abuse (R01) Apply for PA 11 027 Funding Number: PA 11 027 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Continued Development and Maintenance of Software (R01) Apply for PAR 11 028 Funding Number: PAR 11 028 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Statistical Coordination Center for the Population based Research Optimizing Screening through Personalized Regimens (PROSPR)(U01) Apply for RFA CA 11 004 Funding Number: RFA CA 11 004 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Population based Research Optimizing Screening through Personalized Regimens (PROSPR) (U54) Apply for RFA CA 11 003 Funding Number: RFA CA 11 003 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
| Functional Genetics, Epigenetics, and Non coding RNAs in Drug Addiction (R21) Apply for PA 11 034 Funding Number: PA 11 034 Agency: National Institutes of Health Category: Education Health Funding Amount: $275,000 |
| Functional Genetics, Epigenetics, and Non coding RNAs in Drug Addiction (R03) Apply for PA 11 035 Funding Number: PA 11 035 Agency: National Institutes of Health Category: Education Health Funding Amount: Case Dependent |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Subscribe to Leads
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "PA 10 290", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.